Neurology News

A phase 2 clinical trial of dalzanemdor in those with cognitive impairment associated with Huntington’s disease failed to meet its primary and secondary endpoints, causing the manufacturer to halt development of the investigational therapy.

According to published results, the use of gabapentinoids may be associated with an increased risk of hip fractures in older, frail patients and patients with chronic kidney disease.

For individuals with ALS, a daily dosing regimen of oral edaravone was nonsuperior to an FDA-approved staggered regimen of the drug plus placebo, according to a poster presented at AANEM.

In an open-label extension of the CLARITY-AD study, treatment with IV lecanemab was associated with significant improvement in Alzheimer’s disease-related pathology, continuing a positive treatment effect from the randomization phase.

Hypertension, atrial fibrillation and smoking were most strongly associated with an increased risk for severe compared with non-severe stroke, according to analysis from the INTERSTROKE study.

All stages of research on Alzheimer’s disease and related dementias should include increased public and participant involvement so the benefits are seen across diverse populations, according to a position paper in Alzheimer’s & Dementia.

CHICAGO — In the BRAIN-AF trial, daily rivaroxaban did not reduce the incidence of cognitive decline, stroke or transient ischemic attack, compared with placebo, among younger patients with atrial fibrillation and low stroke risk.

WASHINGTON — Herpes zoster vaccination is effective in patients with systemic lupus erythematosus and multiple sclerosis, without increasing the risk for severe lupus flares, according to data presented at ACR Convergence 2024.

Affecting more than 1 billion people worldwide, migraine is among the most common neurological diseases. During their lives, 43% of women and 18% of men develop migraine.